Donghong Xu
Overview
Explore the profile of Donghong Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu D, Lutz J, Divanji P, Li J, Benattia Y, Griffith A, et al.
Clin Pharmacokinet
. 2025 Feb;
PMID: 39907965
Background And Objective: Aficamten, a small-molecule, selective cardiac myosin inhibitor, is under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is primarily eliminated by hepatic metabolism with...
2.
Ma P, Shao H, Xu D, Qi X
J Bioenerg Biomembr
. 2025 Jan;
57(1):49-55.
PMID: 39754634
To investigate the role of silent information regulator 6 (SIRT6) in regulating podocyte injury in diabetic nephropathy (DN) through autophagy mediated by Notch signaling pathway. A blank control group (group...
3.
Xu D, Divanji P, Griffith A, Sukhun R, Cheplo K, Li J, et al.
Pharmacol Res Perspect
. 2024 Sep;
12(5):e70006.
PMID: 39257068
Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and...
4.
Sukhun R, Cremin P, Xu D, Zamora J, Cheung J, Ashcraft L, et al.
Xenobiotica
. 2024 Aug;
54(9):686-700.
PMID: 39102472
Aficamten, a small molecule selective inhibitor of cardiac myosin, was characterised in preclinical and studies.Protein binding in human plasma was 10.4% unbound and ranged from 1.6% to 24.9% unbound across...
5.
Zhao X, Liu H, Tian W, Fang L, Yu M, Wu X, et al.
Front Pharmacol
. 2023 Sep;
14:1227470.
PMID: 37680714
Aficamten is a selective, small-molecule allosteric inhibitor of cardiac sarcomere being developed as a chronic oral treatment for patients with symptomatic obstructive hypertrophic cardiomyopathy. This was the first-in-Chinese study aiming...
6.
Malik F, Robertson L, Armas D, Robbie E, Osmukhina A, Xu D, et al.
JACC Basic Transl Sci
. 2022 Sep;
7(8):763-775.
PMID: 36061336
This phase 1, randomized, double-blind, placebo-controlled study of aficamten (formerly CK-3773274) in healthy adults identified a pharmacologically active range of doses and exposures. At doses that were pharmacologically active (single...
7.
Collibee S, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, et al.
J Med Chem
. 2021 Oct;
64(20):14930-14941.
PMID: 34636234
The discovery of reldesemtiv, a second-generation fast skeletal muscle troponin activator (FSTA) that increases force production at submaximal stimulation frequencies, is reported. Property-based optimization of high throughput screening hit led...
8.
Collibee S, Bergnes G, Muci A, Browne 4th W, Garard M, Hinken A, et al.
ACS Med Chem Lett
. 2018 Apr;
9(4):354-358.
PMID: 29670700
The identification and optimization of the first activators of fast skeletal muscle are reported. Compound was identified from high-throughput screening (HTS) and subsequently found to improve muscle function via interaction...
9.
Metcalf B, Chuang C, Dufu K, Patel M, Silva-Garcia A, Johnson C, et al.
ACS Med Chem Lett
. 2017 Mar;
8(3):321-326.
PMID: 28337324
We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when...
10.
Shang X, Song C, Du X, Shao H, Xu D, Wang X
Saudi Med J
. 2017 Jan;
38(2):204-208.
PMID: 28133696
To investigate whether there is a difference in carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), carbohydrate antigen 72-4 (CA72-4), and neuron-specific enolase (NSE) between diabetic and non-diabetic patients. Methods: A...